JP2022517866A5 - - Google Patents
Info
- Publication number
- JP2022517866A5 JP2022517866A5 JP2021543533A JP2021543533A JP2022517866A5 JP 2022517866 A5 JP2022517866 A5 JP 2022517866A5 JP 2021543533 A JP2021543533 A JP 2021543533A JP 2021543533 A JP2021543533 A JP 2021543533A JP 2022517866 A5 JP2022517866 A5 JP 2022517866A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- pharmaceutically acceptable
- acceptable salt
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024161770A JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910084801.3 | 2019-01-29 | ||
| CN201910084801 | 2019-01-29 | ||
| PCT/CN2020/073798 WO2020156437A1 (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161770A Division JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517866A JP2022517866A (ja) | 2022-03-10 |
| JP2022517866A5 true JP2022517866A5 (https=) | 2023-02-01 |
| JP7617005B2 JP7617005B2 (ja) | 2025-01-17 |
Family
ID=71841634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543533A Active JP7617005B2 (ja) | 2019-01-29 | 2020-01-22 | Ａｋｔ阻害剤 |
| JP2024161770A Withdrawn JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161770A Withdrawn JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3919491B1 (https=) |
| JP (2) | JP7617005B2 (https=) |
| KR (1) | KR102892239B1 (https=) |
| CN (2) | CN117964620A (https=) |
| AU (1) | AU2020214258B2 (https=) |
| CA (1) | CA3127884A1 (https=) |
| ES (1) | ES3037595T3 (https=) |
| PL (1) | PL3919491T3 (https=) |
| WO (1) | WO2020156437A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115397815B (zh) * | 2020-03-17 | 2024-06-14 | 江苏恒瑞医药股份有限公司 | 稠合二环类衍生物、其制备方法及其在医药上的应用 |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| WO2022017448A1 (zh) * | 2020-07-22 | 2022-01-27 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型 |
| US20230321108A1 (en) * | 2020-07-22 | 2023-10-12 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Unit dosage composition of akt inhibitor |
| US20230286979A1 (en) * | 2020-07-22 | 2023-09-14 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof |
| CN116478156A (zh) * | 2022-01-17 | 2023-07-25 | 南京正大天晴制药有限公司 | 一种akt抑制剂化合物的富马酸盐晶型及其制备方法 |
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| WO2024255883A1 (zh) | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 |
| CN120157686A (zh) * | 2023-12-14 | 2025-06-17 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
| CN121177294B (zh) * | 2025-11-27 | 2026-02-27 | 四川省医学科学院·四川省人民医院 | Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590160A (en) | 2003-11-21 | 2012-07-27 | Array Biopharma Inc | AKT protein kinase inhibitors |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| US20130065908A1 (en) * | 2009-12-07 | 2013-03-14 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| ATE523499T1 (de) | 2006-07-06 | 2011-09-15 | Array Biopharma Inc | Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer |
| CA2656566C (en) | 2006-07-06 | 2014-06-17 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| CN101970415A (zh) | 2008-01-09 | 2011-02-09 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| EA020151B1 (ru) | 2009-10-23 | 2014-09-30 | Эли Лилли Энд Компани | Ингибиторы akt и фармацевтические составы, их содержащие |
| US9580443B2 (en) * | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| EP2920154B1 (en) | 2012-11-16 | 2017-10-11 | Merck Patent GmbH | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
| SG11201701704XA (en) | 2014-09-05 | 2017-04-27 | Arqule Inc | Compositions and methods for treating proliferation disorders |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| CN108503645A (zh) | 2018-03-01 | 2018-09-07 | 山东大学 | 含氨甲基的哌嗪酮类化合物及其制备方法和应用 |
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
-
2020
- 2020-01-22 AU AU2020214258A patent/AU2020214258B2/en active Active
- 2020-01-22 KR KR1020217027161A patent/KR102892239B1/ko active Active
- 2020-01-22 CA CA3127884A patent/CA3127884A1/en active Pending
- 2020-01-22 ES ES20748221T patent/ES3037595T3/es active Active
- 2020-01-22 JP JP2021543533A patent/JP7617005B2/ja active Active
- 2020-01-22 EP EP20748221.7A patent/EP3919491B1/en active Active
- 2020-01-22 WO PCT/CN2020/073798 patent/WO2020156437A1/zh not_active Ceased
- 2020-01-22 CN CN202410142331.2A patent/CN117964620A/zh active Pending
- 2020-01-22 CN CN202080005749.9A patent/CN113272304B/zh active Active
- 2020-01-22 PL PL20748221.7T patent/PL3919491T3/pl unknown
-
2024
- 2024-09-19 JP JP2024161770A patent/JP2024175091A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517866A5 (https=) | ||
| JP2005531553A5 (https=) | ||
| CA2463598A1 (en) | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists | |
| IL292229A (en) | Pharmacological combination of prmt5 inhibitors | |
| JP2022542396A5 (https=) | ||
| JP2022527796A5 (https=) | ||
| ES2639064T3 (es) | Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa | |
| HRP20190748T1 (hr) | Derivati policikličkog amida kao inhibitori cdk9 | |
| HRP20200864T1 (hr) | Dihidronaftiridini i srodni spojevi korisni kao inhibitori kinaze za liječenje proliferativnih bolesti | |
| RU2019126468A (ru) | Ингибитор lsd1, а также способ его получения и его применение | |
| CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
| KR950704320A (ko) | Crf 길항제로서의 피롤로피리미딘(pyrrolopyrimidines as crf antagonists) | |
| CA2545527A1 (en) | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | |
| JP2017503867A5 (https=) | ||
| CA2477967A1 (en) | Purine derivatives as kinase inhibitors | |
| ME02423B (me) | 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA | |
| RU2015156524A (ru) | Новое конденсированное пиримидиновое соединение или его соль | |
| RU2011110908A (ru) | Тиенопиримидины для фармацевтических композиций | |
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d | |
| RU2008141239A (ru) | Соединения тетрагидропиридотиенопиримидина и способы их применения | |
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| WO2008070313A3 (en) | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use | |
| NZ601077A (en) | Use of an adrenal hormone-modifying agent | |
| JP2016501185A5 (https=) | ||
| JP2007513094A5 (https=) |